Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.

ABSTRACT:

Purpose

Three years of adjuvant imatinib is the standard treatment for resected gastrointestinal stromal tumors (GISTs) with rupture, but the recurrence rate is prominently high. We aimed to investigate the efficacy and safety of 5-year adjuvant imatinib compared with 3-year treatment in patients with a ruptured GIST following surgical resection.

Materials and methods

A total of 51 patients were included in the analysis. The assessment of GIST rupture was based on Nishida's classification. Twenty patients who were diagnosed before November 2013 were treated with 5 years of imatinib, and 31 patients who were diagnosed after November 2013 were treated with 3 years of imatinib. We retrospectively compared the clinical outcomes of the two groups.

Results

Baseline characte

SUBMITTER: Kang S 

PROVIDER: S-EPMC9582464 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature